ADIL · CIK 0001513525 · operating
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, focused on developing therapeutics for addiction and related disorders. The company's lead program, AD04, is a serotonin-3 antagonist currently in Phase 3 clinical trials for alcohol use disorder treatment. Beyond its primary focus on addiction, Adial is pursuing additional drug candidates for non-opioid pain reduction and other disease indications, though these programs remain in earlier development stages.
The company operates with a minimal workforce of five full-time employees and maintains a clinical development model typical of early-stage biopharmaceutical firms. Adial has no commercial products on the market and generates no product revenue, relying instead on capital raising and partnerships to fund its research and development activities. The company was incorporated in Delaware in 2010 and is listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.72 | $-2.72 | +24.4% | |
| 2023 | $-3.60 | $-3.60 | -605.9% | |
| 2022 | $-0.51 | $-0.51 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-04 | 0001213900-25-019771 | SEC ↗ |
| 2023-12-31 | 2024-04-01 | 0001213900-24-028701 | SEC ↗ |
| 2022-12-31 | 2023-03-30 | 0001213900-23-024719 | SEC ↗ |
| 2021-12-31 | 2022-03-28 | 0001213900-22-015562 | SEC ↗ |
| 2020-12-31 | 2021-03-22 | 0001213900-21-017009 | SEC ↗ |
| 2019-12-31 | 2020-03-20 | 0001213900-20-007020 | SEC ↗ |
| 2018-12-31 | 2019-02-19 | 0001213900-19-002769 | SEC ↗ |